Intravenous endotoxin challenge in healthy humans: An experimental platform to investigate and modulate systemic inflammation

Journal of Visualized Experiments

Volumn 2016, Issue 111, 2016, Pages

  Fullerton, James N ^a   Segre, Elisabetta ^a   de Maeyer, Roel P H ^a   Maini, Alexander A N ^a   Gilroy, Derek W ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Cell kinetics; Critical illness; Cytokine; Endotoxin; Human experimentation; Immune function; Immunology; Infection; Issue 111; Lipopolysaccharide (LPS); Medicine; Physiology; Sepsis; Systemic inflammatory response syndrome (SIRS); Translation

Indexed keywords

CYTOKINE; ENDOTOXIN; LIPOPOLYSACCHARIDE;

ADULT; BLOOD; BLOOD PRESSURE; BODY TEMPERATURE; BREATHING RATE; CELLULAR IMMUNITY; DRUG EFFECTS; ESCHERICHIA COLI; HEART RATE; HUMAN; HUMORAL IMMUNITY; IMMUNOLOGY; INFLAMMATION; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE COUNT; MALE; PATHOLOGY; YOUNG ADULT;

ADULT; BLOOD PRESSURE; BODY TEMPERATURE; CYTOKINES; ENDOTOXINS; ESCHERICHIA COLI; HEART RATE; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; INFLAMMATION; INFUSIONS, INTRAVENOUS; LEUKOCYTE COUNT; LIPOPOLYSACCHARIDES; MALE; RESPIRATORY RATE; YOUNG ADULT;

EID: 84971517480     PISSN: 1940087X     EISSN: None     Source Type: Journal    
DOI: 10.3791/53913     Document Type: Article

References (40)

1. Nathan, C., & Ding, A. Nonresolving inflammation. Cell. 140 (6), 871-882 (2010).
2. Adhikari, N. K., Fowler, R. A., Bhagwanjee, S., & Rubenfeld, G. D. Critical care and the global burden of critical illness in adults. Lancet. 376 (9749), 1339-1346 (2010).
3. Xu, J. et al. Extracellular histones are major mediators of death in sepsis. Nature medicine. 15 (11), 1318-1321 (2009).
4. Zhang, Q. et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature. 464 (7285), 104-107 (2010).
5. Lorne, E., Dupont, H., & Abraham, E. Toll-like receptors 2 and 4: initiators of non-septic inflammation in critical care medicine? Intensive care medicine. 36 (11), 1826-1835 (2010).
6. Brightbill, H. D. et al. Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors. Science. 285 (5428), 732-736 (1999).
7. Zhang, G., & Ghosh, S. Toll-like receptor-mediated NF-kappaB activation: a phylogenetically conserved paradigm in innate immunity. J Clin Invest. 107 (1), 13-19 (2001).
8. Lawrence, T., & Gilroy, D. W. Chronic inflammation: a failure of resolution? International journal of experimental pathology. 88 (2), 85-94 (2007).
9. Fullerton, J. N., O'Brien, A. J., & Gilroy, D. W. Pathways mediating resolution of inflammation: when enough is too much. The Journal of pathology. 231 8-20 (2013).
10. Fullerton, J. N., O'Brien, A. J., & Gilroy, D. W. Lipid mediators in immune dysfunction after severe inflammation. Trends in Immunology. 35 (1), 12-21 (2014).
11. Seok, J. et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proceedings of the National Academy of Sciences of the United States of America. 110 (9), 3507-3512 (2013).
12. Zolfaghari, P. S., Pinto, B. B., Dyson, A., Singer, M. The metabolic phenotype of rodent sepsis: cause for concern? Intensive Care Medicine Experimental. 1 (6), (2013).
13. Dyson, A., & Singer, M. Animal models of sepsis: why does preclinical efficacy fail to translate to the clinical setting? Critical care medicine. 37 (1 Suppl), S30-37 (2009).
14. Rittirsch, D., Hoesel, L. M., & Ward, P. A. The disconnect between animal models of sepsis and human sepsis. Journal of leukocyte biology. 81 (1), 137-143 (2007).
15. van der Worp, H. B. et al. Can animal models of disease reliably inform human studies? PLoS Med. 7 (3), e1000245 (2010).
16. Calvano, S. E., & Coyle, S. M. Experimental human endotoxemia: a model of the systemic inflammatory response syndrome? Surgical infections. 13 (5), 293-299 (2012).
17. Suffredini, A. F., & Noveck, R. J. Human endotoxin administration as an experimental model in drug development. Clin Pharmacol Ther. 96 (4), 418-422 (2014).
18. Lowry, S. F. Human endotoxemia: a model for mechanistic insight and therapeutic targeting. Shock. 24 Suppl 1 94-100 (2005).
19. Andreasen, A. S. et al. Human endotoxemia as a model of systemic inflammation. Current Medicinal Chemistry. 15 (17), 1697-1705 (2008).
20. Thorn, J. The inflammatory response in humans after inhalation of bacterial endotoxin: a review. Inflamm Res. 50 (5), 254-261 (2001).
21. Basran, A. et al. Roles of neutrophils in the regulation of the extent of human inflammation through delivery of IL-1 and clearance of chemokines. Journal of leukocyte biology. 93 (1), 7-19 (2013).
22. Plovsing, R. R. et al. Transcompartmental inflammatory responses in humans: IV versus endobronchial administration of endotoxin*. Crit Care Med. 42 (7), 1658-1665 (2014).
23. van Eijk, L. T. et al. Gender differences in the innate immune response and vascular reactivity following the administration of endotoxin to human volunteers. Crit Care Med. 35 (6), 1464-1469 (2007).
24. Krabbe, K. S. et al. Ageing is associated with a prolonged fever response in human endotoxemia. Clin Diagn Lab Immunol. 8 (2), 333-338 (2001).
25. Krabbe, K. S. et al. Hypotension during endotoxemia in aged humans. Eur J Anaesthesiol. 18 (9), 572-575 (2001).
26. Engelhardt, R., Mackensen, A., Galanos, C., & Andreesen, R. Biological response to intravenously administered endotoxin in patients with advanced cancer. J Biol Response Mod. 9 (5), 480-491 (1990).
27. Patel, P. N., Shah, R. Y., Ferguson, J. F., & Reilly, M. P. Human experimental endotoxemia in modeling the pathophysiology, genomics, and therapeutics of innate immunity in complex cardiometabolic diseases. Arterioscler Thromb Vasc Biol. 35 (3), 525-534 (2015).
28. Michie, H. R. et al. Tumor necrosis factor and endotoxin induce similar metabolic responses in human beings. Surgery. 104 (2), 280-286 (1988).
29. van Deventer, S. J. et al. Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood. 76 (12), 2520-2526 (1990).
30. Fong, Y. M. et al. The acute splanchnic and peripheral tissue metabolic response to endotoxin in humans. The Journal of clinical investigation. 85 (6), 1896-1904 (1990).
31. Stephens, R. C., O'Malley, C. M., Frumento, R. J., Mythen, M. G., & Bennett-Guerrero, E. Low-dose endotoxin elicits variability in the inflammatory response in healthy volunteers. Journal of endotoxin research. 11 (4), 207-212 (2005).
32. Taudorf, S., Krabbe, K. S., Berg, R. M., Pedersen, B. K., & Moller, K. Human models of low-grade inflammation: bolus versus continuous infusion of endotoxin. Clin Vaccine Immunol. 14 (3), 250-255 (2007).
33. Leentjens, J. et al. Reversal of immunoparalysis in humans in vivo: a double-blind, placebo-controlled, randomized pilot study. Am J Respir Crit Care Med. 186 (9), 838-845 (2012).
34. Hamers, L., Kox, M., & Pickkers, P. Sepsis-induced immunoparalysis: mechanisms, markers, and treatment options. Minerva Anestesiol. 81 (4), 426-439 (2015).
35. Xiao, W. et al. A genomic storm in critically injured humans. The Journal of experimental medicine. 208 (13), 2581-2590 (2011).
36. Williams, W. V. et al. Asystole following endotoxin administration. J Endotoxin Res. 6 (4), 303-306 (2000).
37. van Eijk, L. T., Pickkers, P., Smits, P., Bouw, M. P., & van der Hoeven, J. G. Severe vagal response after endotoxin administration in humans. Intensive Care Med. 30 (12), 2279-2281 (2004).
38. Kox, M. et al. Differential ex vivo and in vivo endotoxin tolerance kinetics following human endotoxemia. Critical care medicine. 39 (8), 1866-1870 (2011).
39. Draisma, A., Pickkers, P., Bouw, M. P., & van der Hoeven, J. G. Development of endotoxin tolerance in humans in vivo. Critical care medicine. 37 (4), 1261-1267 (2009).
40. Anel, R., & Kumar, A. Human endotoxemia and human sepsis: limits to the model. Critical care. 9 (2), 151-152 (2005).